This virtual roundtable was a live online event that we expected to last between 30 and 60 minutes. It is now available on-demand. Randal Ketchem chaired the session, and panelists were invited to briefly describe key projects that they have worked on during which teams have designed therapeutic antibodies. Randal Ketchem then moderated a discussion in which the panel was able to discuss the importance of good antibody design for clinical success, lessons learned from projects and what constitutes best practice.

Moderator: Randal R. Ketchem, Ph.D. SVP Biotherapeutic Discovery and Molecular Design, Just - Evotec Biologics until Dec 2024. now: Ketchem Biotherapeutics Consulting LLC, still supporting Just-Evotec Biologics

Participants:

• Jacqueline Kirchner, Senior Program Officer, Bill & Melinda Gates Foundation: Developing monoclonal antibodies for infectious diseases in low- and middle-income countries.
• Hedda Wardemann, Deputy Director, Vaccines and Biologics, Bill & Melinda Gates Foundation Leading cost-effective vaccine and biologic development for global health priorities.
• Thandi Onami, Senior Program Officer, Bill & Melinda Gates Foundation Championing HIV vaccine research and health equity.
• Mohammad Sajadi, Associate Professor of Medicine, Institute of Human Virology, University Of Maryland, Baltimore Renowned for research on HIV-1 and SARS-CoV-2.
• Daniel Emerling, SVP Therapeutics & Vaccines, Discovery & Development, Annexon Biosciences Innovating therapeutic solutions in neurobiology and ophthalmology.